PT
● MODULE 18 / 20
Antiprotozoal & Anthelmintic Drugs
Use parasite species and life-cycle stage to understand effective treatment and relapse prevention.
Quick revision ↓ Medical Dictionary
FULL CHAPTER EXPLANATION
Deep Learning — Module 18
Read this section in sequence. It moves from drug targets to therapeutic effects, adverse reactions and safe use.
01
Malaria and life-cycle targets
Malaria treatment depends on species, severity, geography and resistance. Blood-stage drugs treat circulating infection, while selected liver-stage agents address dormant hypnozoites of P. vivax and P. ovale. Artemisinin-based combinations pair rapid parasite reduction with a partner drug; monotherapy encourages resistance and is not the standard uncomplicated falciparum strategy. Severe malaria requires urgent supervised treatment, not routine outpatient assumptions. Chloroquine effectiveness is limited by species and regional susceptibility.
02
Radical cure and oxidant risk
Primaquine and tafenoquine can address hypnozoites in appropriate infections, but their oxidant effects create a serious hemolysis risk in G6PD deficiency. Testing, eligibility, pregnancy and breastfeeding considerations are drug specific. A blood-stage response does not prove elimination of dormant liver forms. Quinine can cause cinchonism and hypoglycemia, while several antimalarials have cardiac interaction concerns. Distinguish treatment of illness, radical cure and prophylaxis because the targets and timing differ.
03
Amoebiasis and giardiasis
In invasive Entamoeba histolytica infection, a tissue-active nitroimidazole is followed by an appropriate luminal agent to eradicate intestinal carriage. Symptom improvement after tissue treatment does not necessarily remove luminal organisms. Giardiasis has a different life cycle and can be treated with suitable antiprotozoals chosen for the patient. Accurate diagnosis matters because nonpathogenic intestinal organisms do not justify the same treatment as invasive infection. Rehydration and exposure prevention complement drug treatment.
04
Helminth pharmacology
Albendazole and mebendazole impair parasite microtubule function. Praziquantel alters parasite calcium handling and is useful against selected flukes and tapeworms. Ivermectin acts on parasite glutamate-gated chloride channels and has important nematode indications. Pyrantel produces neuromuscular effects in susceptible intestinal worms. Species, tissue involvement and host factors determine duration and suitability. Tissue-parasite killing may provoke inflammation, so some infections need additional specialist management rather than a generic deworming dose.
05
Other protozoa and clinical integration
Leishmaniasis treatment varies with species, disease form and geography; amphotericin formulations, antimonials and other agents have setting-specific roles. Toxoplasmosis treatment can involve pyrimethamine and a sulfonamide with folinic acid to reduce host marrow toxicity. Pregnancy and immunosuppression alter management. Prevent reinfection by addressing water, food, vectors and contacts where relevant. A drug mechanism helps explain efficacy but does not identify the organism or substitute for epidemiological assessment.
High-Yield Revision
- Blood-stage cure and elimination of dormant malaria liver stages are different goals.
- G6PD status matters before oxidant radical-cure antimalarials.
- Tissue amoebiasis treatment may still need a luminal agent.
Common Exam & Concept Pitfalls
- Do not treat all parasites with one deworming drug.
- A drug that kills a tissue parasite can still trigger harmful host inflammation.
Sources & Further Reading
Curriculum scope checked 23 September 2026. These original study notes summarize established principles; current institutional guidance and product information govern clinical use. Faculty review is pending.
RAHBAR study structure: target → drug action → therapeutic use → adverse effects → monitoring. Use institutional curriculum and faculty guidance for local sequencing, practical requirements and assessment specifications.